Guide to IMMUNOPHARMACOLOGY - Further Reading

This further reading collection is extracted from an open CiteUlike collection compiled by the curation team The papers presented are general not ones we have curated database entries from since those papers are now referenced in the database (with the exception of review articles that include ligand structures). As can be seen these are mostly review articles that are relevant to the scope of the database. We would be pleased to receive recommendations for additions (either to this list or for curation).


  • The spectrum of T cell metabolism in health and disease.
    Bantug GR, Galluzzi L, Kroemer G, Hess C. (2017)
    Nat. Rev. Immunol.,  [Epub ahead of print]. [PMID:28944771]

  • Current insights into the role of human β-defensins in atopic dermatitis.
    Chieosilapatham P, Ogawa H, Niyonsaba F. (2017)
    Clin. Exp. Immunol.,  [Epub ahead of print]. [PMID:28708318]

  • Innate Immune Function of Mitochondrial Metabolism.
    Sancho D, Enamorado M, Garaude J. (2017)
    Front Immunol8: 527. [PMID:28533780]

  • Novel aspects of defensins' involvement in virus-induced autoimmunity in the central nervous system.
    Kazakos EI, Kountouras J, Polyzos SA, Deretzi G. (2017)
    Med. Hypotheses102: 33-36. [PMID:28478826]

  • Mitochondria are the powerhouses of immunity.
    Mills EL, Kelly B, O'Neill LAJ. (2017)
    Nat. Immunol.18 (5): 488-498. [PMID:28418387]

  • Immune checkpoint proteins: exploring their therapeutic potential to regulate atherosclerosis.
    Foks AC, Kuiper J. (2017)
    Br. J. Pharmacol.,  [Epub ahead of print]. [PMID:28369782]

  • Biased agonism and allosteric modulation of G protein-coupled receptor 183 - a 7TM receptor also known as Epstein-Barr virus-induced gene 2.
    Daugvilaite V, Madsen CM, Lückmann M, Echeverria CC, Sailer AW, Frimurer TM, Rosenkilde MM, Benned-Jensen T. (2017)
    Br. J. Pharmacol.174 (13): 2031-2042. [PMID:28369721]

  • Immunology proves a great success for treating systemic autoimmune diseases - a perspective on immunopharmacology: IUPHAR Review 23.
    Ishii M. (2017)
    Br. J. Pharmacol.174 (13): 1875-1880. [PMID:28299772]

  • New checkpoints in cancer immunotherapy.
    Ni L, Dong C. (2017)
    Immunol. Rev.276 (1): 52-65. [PMID:28258699]

  • Mechanisms of immunomodulation by mammalian and viral decoy receptors: insights from structures.
    Felix J, Savvides SN. (2017)
    Nat. Rev. Immunol.17 (2): 112-129. [PMID:28028310]

  • It's a lot of work to be nonallergic.
    Sette A, Schulten V. (2017)
    J. Allergy Clin. Immunol.139 (3): 769-770. [PMID:27993537]

  • PI3Kδ and primary immunodeficiencies.
    Lucas CL, Chandra A, Nejentsev S, Condliffe AM, Okkenhaug K. (2016)
    Nat. Rev. Immunol.16 (11): 702-714. [PMID:27616589]

  • Necroptosis inhibitors as therapeutic targets in inflammation mediated disorders - a review of the current literature and patents.
    Kopalli SR, Kang TB, Koppula S. (2016)
    Expert Opin Ther Pat26 (11): 1239-1256. [PMID:27568917]

  • Regulatory circuits of T cell function in cancer.
    Speiser DE, Ho PC, Verdeil G. (2016)
    Nat. Rev. Immunol.16 (10): 599-611. [PMID:27526640]

  • Clinical significance of T cell metabolic reprogramming in cancer.
    Herbel C, Patsoukis N, Bardhan K, Seth P, Weaver JD, Boussiotis VA. (2016)
    Clin Transl Med5 (1): 29. [PMID:27510264]

  • A guide to immunometabolism for immunologists.
    O'Neill LA, Kishton RJ, Rathmell J. (2016)
    Nat. Rev. Immunol.16 (9): 553-65. [PMID:27396447]

  • Combinatorial antibody libraries: new advances, new immunological insights.
    Lerner RA. (2016)
    Nat. Rev. Immunol.16 (8): 498-508. [PMID:27374636]

  • Therapeutic potential of targeting TBK1 in autoimmune diseases and interferonopathies.
    Hasan M, Yan N. (2016)
    Pharmacol. Res.111: 336-42. [PMID:27353409]

  • Peripheral Immune Cell Populations Associated with Cognitive Deficits and Negative Symptoms of Treatment-Resistant Schizophrenia.
    Fernandez-Egea E, Vértes PE, Flint SM, Turner L, Mustafa S, Hatton A, Smith KG, Lyons PA, Bullmore ET. (2016)
    PLoS ONE11 (5): e0155631. [PMID:27244229]

  • Trained immunity: A program of innate immune memory in health and disease.
    Netea MG, Joosten LA, Latz E, Mills KH, Natoli G, Stunnenberg HG, O'Neill LA, Xavier RJ. (2016)
    Science352 (6284): aaf1098. [PMID:27102489]

  • Development of immuno-oncology drugs - from CTLA4 to PD1 to the next generations.
    Hoos A. (2016)
    Nat Rev Drug Discov15 (4): 235-47. [PMID:26965203]

  • Cannabinoids and autoimmune diseases: A systematic review.
    Katchan V, David P, Shoenfeld Y. (2016)
    Autoimmun Rev15 (6): 513-28. [PMID:26876387]

  • Immunometabolism governs dendritic cell and macrophage function.
    O'Neill LA, Pearce EJ. (2016)
    J. Exp. Med.213 (1): 15-23. [PMID:26694970]

  • Inflammaging and Anti-Inflammaging: The Role of Cytokines in Extreme Longevity.
    Minciullo PL, Catalano A, Mandraffino G, Casciaro M, Crucitti A, Maltese G, Morabito N, Lasco A, Gangemi S, Basile G. (2016)
    Arch. Immunol. Ther. Exp. (Warsz.)64 (2): 111-26. [PMID:26658771]

  • Monoclonal antibodies: the new magic bullets for allergy: IUPHAR Review 17.
    Landolina N, Levi-Schaffer F. (2016)
    Br. J. Pharmacol.173 (5): 793-803. [PMID:26620589]

  • Role of neutrophils in atherogenesis: an update.
    Pende A, Artom N, Bertolotto M, Montecucco F, Dallegri F. (2016)
    Eur. J. Clin. Invest.46 (3): 252-63. [PMID:26573245]

  • Combination cancer immunotherapy and new immunomodulatory targets.
    Mahoney KM, Rennert PD, Freeman GJ. (2015)
    Nat Rev Drug Discov14 (8): 561-84. [PMID:26228759]

  • The life (and death) of CD4+ CD28(null) T cells in inflammatory diseases.
    Dumitriu IE. (2015)
    Immunology146 (2): 185-93. [PMID:26190355]

  • Checkpoint blockade for cancer therapy: revitalizing a suppressed immune system.
    Pico de Coaña Y, Choudhury A, Kiessling R. (2015)
    Trends Mol Med21 (8): 482-91. [PMID:26091825]

  • Regulation of tumour necrosis factor signalling: live or let die.
    Brenner D, Blaser H, Mak TW. (2015)
    Nat. Rev. Immunol.15 (6): 362-74. [PMID:26008591]

  • TNF and TNF-receptors: From mediators of cell death and inflammation to therapeutic giants - past, present and future.
    Sedger LM, McDermott MF. (2014)
    Cytokine Growth Factor Rev.25 (4): 453-72. [PMID:25169849]

  • Immunological mechanism of action and clinical profile of disease-modifying treatments in multiple sclerosis.
    Du Pasquier RA, Pinschewer DD, Merkler D. (2014)
    CNS Drugs28 (6): 535-58. [PMID:24723124]

  • Immunologic therapeutics and psychotic disorders.
    Bullmore ET, Lynall ME. (2014)
    Biol. Psychiatry75 (4): 260-1. [PMID:24439554]

  • Mast cells, glia and neuroinflammation: partners in crime?.
    Skaper SD, Facci L, Giusti P. (2014)
    Immunology141 (3): 314-27. [PMID:24032675]

  • The atypical PKCs in inflammation: NF-κB and beyond.
    Diaz-Meco MT, Moscat J. (2012)
    Immunol. Rev.246 (1): 154-67. [PMID:22435553]

  • Humanized mice for modeling human infectious disease: challenges, progress, and outlook.
    Legrand N, Ploss A, Balling R, Becker PD, Borsotti C, Brezillon N, Debarry J, de Jong Y, Deng H, Di Santo JP et al.. (2009)
    Cell Host Microbe6 (1): 5-9. [PMID:19616761]

Other Reading

  • Multi-functional effects of a small-molecule STAT3 inhibitor on NASH and HCC in mice.
    Jung KH, Yoo W, Stevenson HL, Deshpande D, Shen H, Gagea M, Yoo SY, Wang J, Eckols TK, Bharadwaj U et al.. (2017)
    Clin. Cancer Res.,  [Epub ahead of print]. [PMID:28533225]

  • Inhibition of KDM4A activity as a strategy to suppress interleukin-6 production and attenuate colitis induction.
    Ishiguro K, Watanabe O, Nakamura M, Yamamura T, Matsushita M, Goto H, Hirooka Y. (2017)
    Clin. Immunol.180: 120-127. [PMID:28511912]

  • Cannabinoid CB2 receptor ligand profiling reveals biased signalling and off-target activity.
    Soethoudt M, Grether U, Fingerle J, Grim TW, Fezza F, de Petrocellis L, Ullmer C, Rothenhäusler B, Perret C, van Gils N et al.. (2017)
    Nat Commun8: 13958. [PMID:28045021]

  • Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata.
    Mackay-Wiggan J, Jabbari A, Nguyen N, Cerise JE, Clark C, Ulerio G, Furniss M, Vaughan R, Christiano AM, Clynes R. (2016)
    JCI Insight1 (15): e89790. [PMID:27699253]

  • PI3Kγ is a molecular switch that controls immune suppression.
    Kaneda MM, Messer KS, Ralainirina N, Li H, Leem CJ, Gorjestani S, Woo G, Nguyen AV, Figueiredo CC, Foubert P et al.. (2016)
    Nature539 (7629): 437-442. [PMID:27642729]

  • Intestinal Epithelial Cell-Intrinsic Deletion of Setd7 Identifies Role for Developmental Pathways in Immunity to Helminth Infection.
    Oudhoff MJ, Antignano F, Chenery AL, Burrows K, Redpath SA, Braam MJ, Perona-Wright G, Zaph C. (2016)
    PLoS Pathog.12 (9): e1005876. [PMID:27598373]

  • Vagus nerve stimulation inhibits cytokine production and attenuates disease severity in rheumatoid arthritis.
    Koopman FA, Chavan SS, Miljko S, Grazio S, Sokolovic S, Schuurman PR, Mehta AD, Levine YA, Faltys M, Zitnik R et al.. (2016)
    Proc. Natl. Acad. Sci. U.S.A.113 (29): 8284-9. [PMID:27382171]

  • A human and animal model-based approach to investigating the anti-inflammatory profile and potential of the 5-HT2B receptor antagonist AM1030.
    Palmqvist N, Siller M, Klint C, Sjödin A. (2016)
    J Inflamm (Lond)13: 20. [PMID:27340371]

  • Transcriptomics in Interferon-α-Treated Patients Identifies Inflammation-, Neuroplasticity- and Oxidative Stress-Related Signatures as Predictors and Correlates of Depression.
    Hepgul N, Cattaneo A, Agarwal K, Baraldi S, Borsini A, Bufalino C, Forton DM, Mondelli V, Nikkheslat N, Lopizzo N et al.. (2016)
    Neuropsychopharmacology41 (10): 2502-11. [PMID:27067128]

  • Notch Antagonists: Potential Modulators of Cancer and Inflammatory Diseases.
    Kumar R, Juillerat-Jeanneret L, Golshayan D. (2016)
    J. Med. Chem.59 (17): 7719-37. [PMID:27045975]

  • SOCS2: physiological and pathological functions.
    Letellier E, Haan S. (2016)
    Front Biosci (Elite Ed)8: 189-204. [PMID:26709655]

  • What is the evidence for the role of TRP channels in inflammatory and immune cells?.
    Parenti A, De Logu F, Geppetti P, Benemei S. (2016)
    Br. J. Pharmacol.173 (6): 953-69. [PMID:26603538]

  • CD39 is a promising therapeutic antibody target for the treatment of soft tissue sarcoma.
    Hayes GM, Cairns B, Levashova Z, Chinn L, Perez M, Theunissen JW, Liao-Chan S, Bermudez A, Flory MR, Schweighofer KJ et al.. (2015)
    Am J Transl Res7 (6): 1181-8. [PMID:26279761]

  • Activation of protease‑activated receptor‑2 is associated with increased expression of inflammatory factors in the adipose tissues of obese mice.
    Li M, Yang X, Zhang Y, Chen L, Lu H, Li X, Yin L, Zhi X. (2015)
    Mol Med Rep12 (4): 6227-34. [PMID:26252901]

  • Kinase inhibition, competitive binding and proteasomal degradation: resolving the molecular function of the suppressor of cytokine signaling (SOCS) proteins.
    Linossi EM, Nicholson SE. (2015)
    Immunol. Rev.266 (1): 123-33. [PMID:26085211]

  • Combining three antibodies nullifies feedback-mediated resistance to erlotinib in lung cancer.
    Mancini M, Gaborit N, Lindzen M, Salame TM, Dall'Ora M, Sevilla-Sharon M, Abdul-Hai A, Downward J, Yarden Y. (2015)
    Sci Signal8 (379): ra53. [PMID:26038598]

  • Pan-HER, an Antibody Mixture Simultaneously Targeting EGFR, HER2, and HER3, Effectively Overcomes Tumor Heterogeneity and Plasticity.
    Jacobsen HJ, Poulsen TT, Dahlman A, Kjær I, Koefoed K, Sen JW, Weilguny D, Bjerregaard B, Andersen CR, Horak ID et al.. (2015)
    Clin. Cancer Res.21 (18): 4110-22. [PMID:25908781]

  • Molecular properties of human IgG subclasses and their implications for designing therapeutic monoclonal antibodies against infectious diseases.
    Irani V, Guy AJ, Andrew D, Beeson JG, Ramsland PA, Richards JS. (2015)
    Mol. Immunol.67 (2 Pt A): 171-82. [PMID:25900877]

  • Gene delivery of suppressors of cytokine signaling (SOCS) inhibits inflammation and atherosclerosis development in mice.
    Recio C, Oguiza A, Mallavia B, Lazaro I, Ortiz-Muñoz G, Lopez-Franco O, Egido J, Gomez-Guerrero C. (2015)
    Basic Res. Cardiol.110 (2): 8. [PMID:25604439]

  • L-type amino-acid transporter 1 (LAT1): a therapeutic target supporting growth and survival of T-cell lymphoblastic lymphoma/T-cell acute lymphoblastic leukemia.
    Rosilio C, Nebout M, Imbert V, Griessinger E, Neffati Z, Benadiba J, Hagenbeek T, Spits H, Reverso J, Ambrosetti D et al.. (2015)
    Leukemia29 (6): 1253-66. [PMID:25482130]

  • Effect of the aspartic acid D2 on the affinity of Polybia-MP1 to anionic lipid vesicles.
    Leite NB, Dos Santos Alvares D, de Souza BM, Palma MS, Ruggiero Neto J. (2014)
    Eur. Biophys. J.43 (4-5): 121-30. [PMID:24595375]

  • Anti-CD39 and anti-CD73 antibodies A1 and 7G2 improve targeted therapy in ovarian cancer by blocking adenosine-dependent immune evasion.
    Häusler SF, Del Barrio IM, Diessner J, Stein RG, Strohschein J, Hönig A, Dietl J, Wischhusen J. (2014)
    Am J Transl Res6 (2): 129-39. [PMID:24489992]

  • Regulation of Janus kinases by SOCS proteins.
    Kershaw NJ, Murphy JM, Lucet IS, Nicola NA, Babon JJ. (2013)
    Biochem. Soc. Trans.41 (4): 1042-7. [PMID:23863176]

  • Group 2 innate lymphoid cells show up in the skin.
    Spits H. (2013)
    Immunol. Cell Biol.91 (6): 390-2. [PMID:23732616]

  • Type 2 innate lymphoid cells-new members of the "type 2 franchise" that mediate allergic airway inflammation.
    Mjösberg J, Spits H. (2012)
    Eur. J. Immunol.42 (5): 1093-6. [PMID:22539283]

  • The cholinergic anti-inflammatory pathway: a missing link in neuroimmunomodulation.
    Pavlov VA, Wang H, Czura CJ, Friedman SG, Tracey KJ. (2003)
    Mol. Med.9 (5-8): 125-34. [PMID:14571320]